Overall results
VULVOVAGINAL CANDIDIASIS
Ibrexafungerp treatment resulted in similar improvements in all efficacy end points, all of which were statistically superior to placebo in VANISH 303, VANISH 306, and in the pooled analysis (Efficacy outcomes for the VANISH 303, VANISH 306, and pooled analysis studies. BID, twice daily; mITT, modified intention to treat.The percentage of patients with complete symptom resolution at the follow-up visit (symptom score = 0 without having received rescue antifungal treatment regardless of having achieved a clinical cure at the test-of-cure visit) was also significantly higher with ibrexafungerp (66.8% vs. 48.4%; RR, 1.35; 95% CI, 1.15–1.59; In the pooled analysis, patients with vulvovaginal candidiasis (caused predominantly by baseline 